Caspofungin Acetate

CHEMBL5314378 Phase 4 معتمد Small molecule

Half-Life

—

Bioavailability

—

Protein Binding

—

Molecular Weight

1213.4 g/mol

LogP

—

Phase

4

The acetate salt form of caspofungin, administered intravenously for serious invasive fungal infections including candidemia and invasive aspergillosis. It disrupts fungal cell wall integrity through inhibition of glucan synthesis. Liver function should be monitored during treatment, as dose adjustment may be needed in hepatic impairment.

الوزن الجزيئي

1213,4000 g/mol

TPSA

487,00 Å²

المجالات العلاجية

Ovarian Cancer Pancreatic Cancer Bladder Cancer Thyroid Cancer Non-Small Cell Lung Cancer Chronic Obstructive Pulmonary Disease Non-Alcoholic Fatty Liver Disease Obesity Lymphoma Breast Cancer Prostate Cancer Colorectal Cancer Leukemia

Pharmacokinetics (PK)

Pharmacodynamics (PD)

البنية ثنائية الأبعاد

SVG PNG

Cite this structure

Embed this structure

SMILES

CC(=O)O.CC(=O)O.CC[C@H](C)C[C@H](C)CCCCCCCCC(=O)N[C@H]1C[C@@H](O)[C@@H](NCCN)NC(=O)[C@@H]2[C@@H](O)CCN2C(=O)[C@H]([C@H](O)CCN)NC(=O)[C@H]([C@H](O)[C@@H](O)c2ccc(O)cc2)NC(=O)[C@@H]2C[C@@H](O)CN2C(=O)[C@H]([C@@H](C)O)NC1=O

InChI

InChI=1S/C52H88N10O15.2C2H4O2/c1-5-28(2)24-29(3)12-10-8-6-7-9-11-13-39(69)56-34-26-38(68)46(55-22-21-54)60-50(75)43-37(67)19-23-61(43)52(77)41(36(66)18-20-53)58-49(74)42(45(71)44(70)31-14-16-32(64)17-15-31)59-48(73)35-25-33(65)27-62(35)51(76)40(30(4)63)57-47(34)72;2*1-2(3)4/h14-17,28-30,33-38,40-46,55,63-68,70-71H,5-13,18-27,53-54H2,1-4H3,(H,56,69)(H,57,72)(H,58,74)(H,59,73)(H,60,75);2*1H3,(H,3,4)/t28-,29+,30+,33+,34-,35-,36+,37-,38+,40-,41-,42-,43-,44-,45-,46-;;/m0../s1

Molecular Formula

C56H96N10O19

HBD / HBA

18 / 22

الروابط القابلة للدوران

23

الذرات الثقيلة

85

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

الأسئلة الشائعة

The acetate salt form of caspofungin, administered intravenously for serious invasive fungal infections including candidemia and invasive aspergillosis. It disrupts fungal cell wall integrity through inhibition of glucan synthesis. Liver function should be monitored during treatment, as dose adjustment may be needed in hepatic impairment.

Yes, Caspofungin Acetate is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

ChEMBL — European Bioinformatics Institute (EBI). CHEMBL5314378. Open-access bioactivity database.
PubChem — National Center for Biotechnology Information (NCBI). CID 6850808. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

PillFYI

هل تبحث عن معلومات ملائمة للمرضى؟

Caspofungin Acetate على PillFYI

البنية

بيانات سريعة

الصيغة الجزيئية: C56H96N10O19
المرادفات: 1

روابط خارجية

Cite

BibTeX, APA, MLA, Chicago, IEEE, Harvard

إخلاء المسؤولية الطبية

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.